Advertisement
Advertisement
XGN
Exagen Inc. Common Stock
6.87
USDSponsored
+0.28
+4.25%
Aug 07, 15:59 UTC -4
Closed
After-Market
6.87
0.00
0.00%
XGN Earnings Reports
Positive Surprise Ratio
XGN beat 22 of 28 last estimates.
79%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$18.58M
/-$0.17
Implied change from Q2 26 (Revenue/ EPS)
-6.80%
/+30.77%
Implied change from Q3 25 (Revenue/ EPS)
+7.77%
/-45.16%
Exagen Inc. Common Stock earnings per share and revenue
On Aug 04, 2026, XGN reported earnings of -0.13 USD per share (EPS) for Q2 26, beating the estimate of -0.19 USD, resulting in a 32.26% surprise. Revenue reached 19.94 million, compared to an expected 18.00 million, with a 10.80% difference. The market reacted with a +37.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.17 USD, with revenue projected to reach 18.58 million USD, implying an increase of 30.77% EPS, and decrease of -6.80% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Trulieve Cannabis Corp.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$0.06
Actual
$0.11
Surprise
+72.14%
BioLife Solutions Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.04
Actual
-$0.02
Surprise
+54.65%
Canopy Growth Corporation Common Shares
Report Date
Aug 07, 2026 For Q1 27
Estimate
-$0.11
Actual
-$0.02
Surprise
+75.74%
TriSalus Life Sciences, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.16
Surprise
-1.20%
Apyx Medical Corporation Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+16.27%
ResMed Inc.
Report Date
Aug 06, 2026 For Q4 26
Estimate
$2.91
Actual
$2.95
Surprise
+1.09%
ICU Medical Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.95
Actual
$2.37
Surprise
+21.43%
Haemonetics Corporation
Report Date
Aug 06, 2026 For Q1 27
Estimate
$1.08
Actual
$1.13
Surprise
+4.82%
United-Guardian, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
-Actual
$0.16
Surprise
-
FAQ
What were Exagen Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Exagen Inc. Common Stock reported EPS of -$0.13, beating estimates by 32.26%, and revenue of $19.94M, 10.8% above expectations.
How did the market react to Exagen Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 37.82%, changed from $4.68 before the earnings release to $6.45 the day after.
When is Exagen Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Exagen Inc. Common Stock's next earnings report?
Based on 9
analysts, Exagen Inc. Common Stock is expected to report EPS of -$0.17 and revenue of $18.58M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement